IGF-1 DES

IGF-1 DES is a truncated form of insulin-like growth factor 1 missing the first three amino acids of the N-terminus, a modification that markedly reduces its affinity for IGF-binding proteins. This gives it substantially greater potency at the IGF-1 receptor relative to native IGF-1, but only for a very short window, since it is cleared from circulation quickly. It is studied primarily for localized, site-specific muscle growth when injected directly into a trained muscle. Human clinical data are limited, and most supporting evidence comes from animal and in vitro studies. Reported benefits include high potency at the igf-1 receptor per unit dose, proposed localized hypertrophic effect at the injection site, short duration of action may allow more precise timing around training sessions.

Reported ranges run 20-60 mcg. A low protocol is 20 mcg once daily on training days, and a high protocol is 60 mcg once daily on training days. This is reference information, not a dosing recommendation.

Approximately 20-30 minutes. That is what sets the dosing frequency, and it is why the timing guidance is ~20 min before a workout.

Intramuscular: into muscle. Typically injected directly into the trained muscle immediately after exercise because of its very short half-life; some protocols use subcutaneous injection instead.

4-6 weeks on, followed by 4-6 weeks off. Because of its localized, acute action, cycling is typically framed around training blocks rather than continuous administration.

Reported side effects include localized swelling or discomfort at the injection site, hypoglycemia risk, particularly if combined with insulin, theoretical concern for promoting abnormal cell growth given potent growth-factor activity, very short half-life limits the window for effect, which some view as a practical drawback. Evidence level for this compound is emerging research.